ストックスクリーナーアプリを入手
21.51
1.37%
0.29
アフターアワーズ：
21.51
前日終値:
$21.22
開ける：
$21.39
24時間の取引高:
816.55K
Relative Volume:
1.03
時価総額：
$1.05B
収益：
$109.79M
当期純損益:
$-153.49M
株価収益率:
-6.7014
EPS:
-3.2098
ネットキャッシュフロー:
$-172.59M
1週間 パフォーマンス:
+12.62%
1か月 パフォーマンス:
+16.65%
6か月 パフォーマンス:
+24.41%
1年 パフォーマンス:
+100.09%
1日の値動き範囲:
$20.65
$21.53
1週間の範囲:
$18.70
$22.02
52週間の値動き範囲:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
21.51 | 1.03B | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Jefferies | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-06-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-19 | 再開されました | Ladenburg Thalmann | Buy |
| 2024-08-22 | 開始されました | Guggenheim | Buy |
| 2023-02-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-27 | 開始されました | Berenberg | Buy |
| 2020-04-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-09 | 開始されました | National Securities | Neutral |
| 2019-05-30 | 開始されました | JP Morgan | Neutral |
| 2019-05-29 | 開始されました | Goldman | Neutral |
| 2019-01-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-04-04 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-11-15 | 繰り返されました | Oppenheimer | Outperform |
| 2017-11-15 | ダウングレード | Raymond James | Outperform → Mkt Perform |
すべてを表示
Urogen Pharma Ltd (URGN) 最新ニュース
Market Pulse: Is now the right time to enter UroGen Pharma LtdPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Discipline and Rules-Based Execution in URGN Response - Stock Traders Daily
UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push - Sahm
URGN SEC FilingsUrogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Sahm
UroGen Pharma Ltd. Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment Of Patients with Low-Grade Upper Tract Urothelial Cancer - marketscreener.com
UroGen Launches LG-UTUC Luminaries Initiative Recognizing - GlobeNewswire
Trend Report: Will UroGen Pharma Ltd stock benefit from M AEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bull Bear: What are the risks of holding UroGen Pharma LtdWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Trend Recap: Is UroGen Pharma Ltd a cyclical or defensive stock2026 Reactions & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady - Yahoo Finance
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma Ltd.Ordinary Shares (NQ: URGN - The Chronicle-Journal
UroGen Pharma Ltd (UR8.DU) Income Statement - ca.finance.yahoo.com
Behavioral Patterns of URGN and Institutional Flows - Stock Traders Daily
Activity Recap: Will UroGen Pharma Ltd stock benefit from M AMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - MarketBeat
UroGen’s Zusduri shows 72% event-free rate at 24 months By Investing.com - Investing.com South Africa
UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus
UroGen’s Zusduri shows 72% event-free rate at 24 months - Investing.com
Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - marketscreener.com
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - GlobeNewswire
URGN PE Ratio & Valuation, Is URGN Overvalued - Intellectia AI
Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Is UroGen Pharma Ltd a cyclical or defensive stockTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN - MarketBeat
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology - Traders Union
Forecast Cut: Can UroGen Pharma Ltd keep up with sector leaders2026 Retail Activity & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
UroGen Pharma Hits Day High with Strong 7.12% Intraday Surge - Markets Mojo
How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance
Live UroGen Pharma Ltd. (URGN) Technical Analysis - Traders Union
UroGen Pharma Ltd. (URGN) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
UroGen Pharma Ltd. (URGN) Stock Price Prediction for 2026, 2030-2040 - Traders Union
PGIM Total Return Bond ETF declares monthly distribution of $0.1527 - MSN
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Clinical Setbacks and Cash Burn Con - AD HOC NEWS
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Biotech Sector Volatility - AD HOC NEWS
UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R - GuruFocus
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence - The Manila Times
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report - GlobeNewswire
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support - GlobeNewswire Inc.
Jobs Data: Is UroGen Pharma Ltd stock showing strong momentumMarket Volume Report & Consistent Profit Trading Strategies - baoquankhu1.vn
URGN (UroGen Pharma) NonCurrent Deferred Revenue : $0.0 Mil (As of Dec. 2025) - GuruFocus
How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily
URGN Technical Analysis & ETF Price Forecast - Intellectia AI
Urogen Pharma Ltd (URGN) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):